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Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer
(mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in
the clinical practice.
Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on
data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety
according to the age categories.
Results: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged <65 years, 65 to 75 years, and
75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients
aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5,
and 25.1 months for patients aged <65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable
Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in
bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which
was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged <65 years, 65 to 75 years, and 75+ years, respectively.
Conclusions: The results of the present study suggest similar outcome in terms of OS and PFS with
bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy
compared to younger patients. Thus, chronological age should not be considered to represent a limitation in
prescribing bevacizumab-containing therapy in mCRC patients.
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Colorectal cancer (CRC) represents a serious public health
problem in the Czech Republic as the Czech population
presently ranks 3rd in international statistics of age-
standardised CRC incidence rates, with 78 new cases
of CRC being diagnosed annually per 100,000 inhabitants
(2010) [1]. In addition, more than one quarter of these
patients have metastatic disease at the time of diagnosis
[2]. Over the past decade, however, the introduction of
new cytotoxic drugs, targeted therapy, and an increase in* Correspondence: dusek@iba.muni.cz
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unless otherwise stated.the use of liver resection have resulted in significantly
improved outcomes in metastatic CRC (mCRC) patients
[3,4]. Monoclonal antibodies, the targeted agents cur-
rently used in the treatment of mCRC are usually utilised
in combination with cytotoxic drugs. The first and cur-
rently most widely used monoclonal antibody in mCRC
therapy is bevacizumab (F. Hoffman-La Roche Ltd.,
Basel, Switzerland), a drug targeting the vascular endo-
thelial growth factor. Efficacy and safety of bevacizumab
administered in combination with chemotherapy back-
bone regimens in patients with mCRC have been the
subject of several randomised clinical trials [5-7] as well
as observational studies [8,9]. Although patients ≥65 years
of age represent the majority of patients with mCRC, thisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trials and very likely undertreated in the clinical practice
[10,11]. However, the results of recently published rando-
mised trials as well as observational studies [12-15] sug-
gest that bevacizumab provides similar overall survival
(OS) and progression-free survival (PFS) benefits in
patients aged ≥65 years compared to younger patients.
In the present study, we have analysed the data from
the Czech national registry of mCRC patients treated
with first-line bevacizumab with the aim to compare the
treatment outcomes according to age.
Methods
Patients
Adult mCRC patients treated with first-line bevacizumab-
containing therapy in the Czech Republic were included
in the present analysis. In the Czech Republic, the admin-
istration of targeted therapy is concentrated to compre-
hensive cancer centres and these drugs are reimbursed
only when administered in one of these centres. The data
set was obtained from the Czech population-based, retro-
spective, observational CORECT registry [16] which con-
tains de-identified data of the Czech mCRC patients
treated with targeted therapies including bevacizumab,
cetuximab, and panitumumab. The protocol was approved
by the independent ethics committee at each participating
centre (Ethics Committee (EC) of the Ceske Budejovice
Hospital, EC of the Chomutov Hospital, EC of the General
University Hospital in Prague, EC of the Jihlava Hospital,
EC of the Liberec Regional Hospital, EC of the Masaryk
Hospital in Usti nad Labem, EC of the Masaryk Memorial
Cancer Institute in Brno, EC of the Na Bulovce Hospital in
Prague, EC of the Na Homolce Hospital in Prague, EC of
the Novy Jicin Hospital, EC of the Pardubice Regional
Hospital, EC of the St. Anne’s University Hospital (UH) in
Brno, EC of the Thomayer Hospital in Prague, EC of the
Tomas Bata Regional Hospital in Zlin, EC of the UH Brno,
EC of the UH Hradec Kralove, EC of the UH in Motol,
Prague, EC of the UH Olomouc, EC of the UH Ostrava,
EC of the UH Pilsen) and complied with the International
Ethical Guidelines for Biomedical Research Involving
Human Subjects, Good Clinical Practice guidelines, the
Declaration of Helsinki, and local laws. Based on the re-
cent validation using the data of all health care payers in
the Czech Republic, the CORECT database includes data
of approximately 96% of all mCRC patients treated with
targeted therapies in the country. The data are entered
into the CORECT database by the clinicians and up-
dated at least twice yearly. The final data cut-off date was
30 September 2012.
Outcome assessment
Both OS and PFS were considered the primary efficacy
measures in the present study. Objective response wasassessed using the RECIST criteria. Both OS and PFS were
calculated from the start of bevacizumab-containing ther-
apy. Only patients who started bevacizumab and chemo-
therapy at least six months prior to the data cut-off were
included in the present analysis. Such design ensured
sufficient follow-up for statistically relevant analyses of the
time-to-event endpoints.
Adverse events were assessed using the Common Ter-
minology Criteria for Adverse Events (CTCAE) version
3.0 criteria. The severity of adverse events was classified
by the attending medical oncologist as ‘mild to moderate’
corresponding to grade 1 to 2 toxicity or ‘severe’ corre-
sponding to grade 3 to 4 toxicity. Only toxicities consid-
ered to be related to the administration of bevacizumab
therapy were entered into the database.
In accordance with the World Health Organization, eld-
erly mCRC patients were defined as persons aged ≥65 years.
In some studies, however, the cut-off to define elderly
population was set at age of 75 years. Therefore, in the
present study outcomes were analysed based on the
patients’age at the start of bevacizumab therapy in fol-
lowing subgroups: (1) <65 years, (2) 65 to 75 years, and
(3) ≥75 years.Statistical analysis
Standard descriptive statistics were used to characterise
the data. Differences in categorical parameters as well as
in the incidence of adverse effects among age categories
were assessed using the Pearson chi-square test. Com-
parisons of continuous variables were based on the
Kruskal–Wallis test. The survival was estimated using
the Kaplan–Meier method. Log-rank test was used to com-
pare OS and PFS for different subgroups. Multivariable
Cox proportional hazards model was used to assess the
effect of age on survival in the presence of other poten-
tial predictive and prognostic factors. Standard level of
significance α = 0.05 was used.Results
In total, 3,187 mCRC patients treated with first-line
bevacizumab were analysed. Of those, 2,126 (66.7%), 932
(29.2%), and 129 (4.0%) patients were age <65 years,
65 to 75 years, and ≥75 years, respectively. Baseline
patient characteristics are shown in Table 1. As of 30
September 2012, the median follow-up was 17 months
(range 0.5-84.6 months) with 209 (9.8%), 110 (11.8%), and
17 (13.2%) patients aged <65 years, 65 to 75 years,
and ≥75 years remaining on bevacizumab-containing ther-
apy, respectively. Median duration of bevacizumab therapy
was 7.4 months (range 0.5-58.7 months), 6.9 months
(range 0.5-41.7 months), and 6.4 months (range 0.5-
31.0 months) in the <65 years, 65 to 75 years, and ≥75 years
age cohorts, respectively.
Table 1 Baseline characteristics of analysed patients
Characteristic <65 years (n = 2,126) 65-75 years (n = 932) ≥ 75 years (n = 129) p-valuea
Males, n (%) 1,324 (62.3) 593 (63.6) 79 (61.2) 0.74
Age at treatment initiation
Median (min-max) 57.7 (21.3-64.9) 68.3 (65.0-74.9) 76.9 (75.0-85.2) -
Localization, n (%)
Colon 1,287 (60.5) 571 (61.3) 84 (65.1) 0.57
Rectum 839 (39.5) 361 (38.7) 45 (34.9)
History of thromboembolism, n (%) 68 (3.2) 55 (5.9) 7 (5.4) 0.002
History of hypertension, n (%) 629 (29.6) 494 (53.0) 85 (65.9) <0.001
Primary metastatic, n (%)
M0 804 (37.8) 389 (41.7) 55 (42.6) 0.09
M1 1,322 (62.2) 543 (58.3) 74 (57.4)
Adenocarcinoma, n (%) 2,060 (96.7) 916 (98.3) 127 (98.4) 0.07
Prior surgery, n (%) 1,690 (79.5) 808 (86.7) 117 (90.7) <0.001
Prior radiotherapy, n (%) 437 (20.6) 200 (21.5) 17 (13.2) 0.09
Adjuvant chemotherapy, n (%) 639 (30.1) 302 (32.4) 39 (30.2) 0.43
Site of metastatic disease, n (%)
Liver 1,348 (63.4) 594 (63.7) 99 (76.7) 0.009
Lung 504 (23.7) 240 (25.8) 31 (24.0) 0.48
Other 933 (43.9) 390 (41.8) 41 (31.8) 0.02
Number of metastatic sites, %
1/2/>2 55.5/31.2/13.3 58.6/31.8/9.6 62.7/30.2/7.1 0.02
Chemotherapy regimens, n (%)
FOLFOX 903 (42.5) 394 (42.3) 51 (39.5) <0.001
XELOX 753 (35.4) 313 (33.6) 25 (19.4)
FOLFIRI 199 (9.4) 74 (7.9) 5 (3.9)
XELIRI 127 (6.0) 39 (4.2) 1 (0.8)
Capecitabine 39 (1.8) 44 (4.7) 18 (14.0)
5-FU/LV 21 (1.0) 21 (2.3) 23 (17.8)
Other 67 (3.2) 32 (3.4) 3 (2.3)
Without CT 17 (0.8) 15 (1.6) 3 (2.3)
PS at bevacizumab initiation, n (%)
0 612 (28.8) 256 (27.5) 41 (31.8) 0.02
1 549 (25.8) 279 (29.9) 39 (30.2)
2-3 24 (1.1) 15 (1.6) 6 (4.7)
Not available 941 (44.3) 382 (41.0) 43 (33.3)
Treatment duration (months)
Median (min- max) 7.4 (0.5-58.7) 6.9 (0.5-41.7) 6.4 (0.5-31.0) 0.04
Best response, n (%)
CR 332 (15.6) 112 (12.0) 8 (6.2) 0.003
PR 675 (31.7) 271 (29.1) 40 (31.0)
SD 741 (34.9) 381 (40.9) 59 (45.7)
PD 248 (11.7) 107 (11.5) 12 (9.3)
Not available 130 (6.1) 61 (6.5) 10 (7.8)
aKruskal–Wallis test was used for age at treatment initiation and treatment duration, Pearson chi-square test for the rest of variables.
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Figure 2 Overall survival of metastatic colorectal cancer
patients treated with first-line bevacizumab according to the
age categories.
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In most patients across all age subgroups (n = 2,439,
76.5%), bevacizumab was administered in combination
with oxaliplatin-based chemotherapy backbone regimens
including infusional 5-fluorouracil/leucovorin/oxaliplatin
(FOLFOX) and capecitabine/oxaliplatin (XELOX) (Table 1).
However, while the percentage of mCRC patients
receiving FOLFOX was approximately identical in all
age groups, a trend toward decreased use of XELOX
in patients aged ≥75 years was observed. In addition,
chemotherapy regimens containing irinotecan were less
frequently used in patients aged ≥75 years. On the other
hand, fluoropyrimidine monotherapy was more likely to be
used as chemotherapy backbone in patients aged ≥75 years,
and 17.8% and 14.0% of these patients received a 5-
fluororuracil/leucovorin (5-FU/LV) regimen or capecita-
bine, respectively.
Survival outcomes
Median PFS was 11.4 months (95% confidence interval
[CI] 10.9-11.9 months) for patients aged <65 years,
11.3 months (95% CI 10.5-12.0 months) for patients aged
65 to 75 years, and 11.8 months (95% CI 9.6-14.0 months)
for patients ≥75 years (Figure 1). The PFS differences
between age categories were not statistically significant
(p = 0.94). Median OS was 26.9 months (95% CI 25.3-
28.5 months) for patients aged <65 years, 27.5 months
(95% CI 25.0-29.9 months) for patients aged 65 to
75 years, and 25.1 months (95% CI 11.3-38.9 months)
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Figure 1 Progression-free survival of metastatic colorectal
cancer patients treated with first-line bevacizumab according
to the age categories.significant differences in OS were observed between
the age groups (p = 0.73). PFS and OS estimates according
to age categories and chemotherapy backbone regimens
are presented in Table 2.
In order to adjust for the effect of other potential
predictive and prognostic factors that may be associated
with age, multivariable Cox model for both PFS and OS
was designed (Table 3). Similarly to the univariate ana-
lysis, the patient age was not significantly associated with
PFS in the multivariable model. When patients <65 years
were used as the reference, the hazard ratio (HR) was
estimated to be 0.99 (p = 0.88) and 1.01 (p = 0.96) in
patients aged 65 to 75 years and patients aged ≥75 years,
respectively (Table 3). Variables significantly associated
with PFS in the final model included the presence of two
and more metastatic sites, synchronous mCRC, and
rectal primary.
Similarly, in the multivariable Cox model for OS
(Table 3), the patient age was not significantly associated
with OS (patients aged 65 to 75 years: HR = 0.98, p = 0.73;
patients aged ≥75 years: HR = 1.18, p = 0.24). On the other
hand, the number of metastatic sites, the presence of
metastatic disease at the diagnosis of CRC, and the site of
primary tumour were observed to be the strongest inde-
pendent predictors of OS. Patients with three and more
metastatic sites at the start of bevacizumab therapy were
found to have almost two times higher risk of death com-
pared to patients with only one metastatic site, and in
patients with two metastatic sites the risk of death was
increased by more than 40%. Patients with synchronous
Table 2 Progression-free survival (PFS) and overall survival (OS) according to age categories and chemotherapy
backbone regimens
Chemotherapy regimen <65 years 65-75 years ≥75 years
FOLFOX n 903 394 51
Median PFS (95% CI) 11.2 (10.3-12.0) 12.1 (10.9-13.4) 11.8 (8.9-14.7)
Median OS (95% CI) 25.5 (22.8-28.1) 30.7 (27.6-33.7) not reached
XELOX n 753 313 25
Median PFS (95% CI) 11.5 (10.6-12.5) 11.5 (10.3-12.8) 13.2 (10.9-15.5)
Median OS (95% CI) 30.0 (27.3-32.7) 27.0 (23.8-30.2) 25.1 (16.6-33.6)
FOLFIRI n 199 74 5
Median PFS (95% CI) 12.2 (10.7-13.8) 11.3 (9.0-13.6) -
Median OS (95% CI) 25.4 (21.5-29.4) 22.9 (19.9-25.9) -
XELIRI n 127 39 1
Median PFS (95% CI) 14.9 (12.5-17.2) 11.3 (8.4-14.1) -
Median OS (95% CI) 29.1 (22.4-35.9) 26.7 (19.9-33.6) -
Capecitabine n 39 44 18
Median PFS (95% CI) 9.4 (6.1-12.7) 10.3 (4.1-16.5) 13.4 (7.9-18.8)
Median OS (95% CI) 31.1 (27.0-35.2) 17.0 (6.3-27.7) 19.8 (11.8-27.9)
5-FU/LV n 21 21 23
Median PFS (95% CI) 10.1 (4.1-16.1) 5.9 (3.3-8.5) 10.5 (6.9-14.0)
Median OS (95% CI) 22.6 (14.0-31.2) 21.3 (5.4-37.1) 19.4 (10.7-28.2)
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pared to patients with metachronous mCRC.
The multivariable Cox models for PFS and OS were
also calculated on the subset of patients with available
information on performance status (n = 1,821). Similarly
to the entire cohort, the patient age was not observed to
have significant effect on either PFS or OS (data not
shown), whereas the number of metastatic sites and theTable 3 Results of the multivariable Cox model for progressio
Model for PFS Risk/baseline category
Number of metastatic sites 2/1
3 and more/1
Presence of metastasis at diagnosis M1/M0
Site of primary tumour Rectum/Colon
Age 65-75 years/<65 years
>75 years/<65 years
Model for OS Risk/baseline category
Number of metastatic sites 2/1
3 and more/1
Presence of metastasis at diagnosis M1/M0
Site of primary tumour Rectum/Colon
Age 65-75 years/<65 years
>75 years/<65 years
Abbreviations: HR: hazard ratio; CI: confidence interval.presence of metastatic disease at diagnosis were con-
firmed as the strongest prognostic factors with respect
to both PFS and OS.
Safety outcomes
Only bevacizumab-associated toxicity events were reported
to the registry. Safety data are summarised in Table 4. As
expected, the most common bevacizumab-related adversen-free survival (PFS) and overall survival (OS)
Beta HR 95% CI p-value
0.29 1.34 1.22-1.46 <0.001
0.53 1.70 1.50-1.94 <0.001
0.12 1.13 1.03-1.23 0.008
0.09 1.10 1.01-1.19 0.04
−0.01 0.99 0.91-1.09 0.88
0.01 1.01 0.81-1.25 0.96
Beta HR 95% CI p-value
0.34 1.41 1.25-1.59 <0.001
0.66 1.94 1.65-2.27 <0.001
0.23 1.25 1.12-1.41 <0.001
0.12 1.13 1.01-1.26 0.03
−0.02 0.98 0.87-1.11 0.73
0.17 1.18 0.89-1.56 0.24
Table 4 Incidence of bevacizumab-related adverse events
All patients <65 years 65-75 years ≥75 years
(n = 3,187) (n = 2,126) (n = 932) (n = 129)
n (%) n (%) n (%) n (%)
New or worsening hypertension All 115 (3.6) 71 (3.3) 34 (3.6) 10 (7.8)
G3-5 51 (1.6) 31 (1.5) 16 (1.7) 4 (3.1)
Thromboembolic event All 105 (3.3) 65 (3.1) 36 (3.9) 4 (3.1)
G3-5 82 (2.6) 49 (2.3) 30 (3.2) 3 (2.3)
Proteinuria All 59 (1.9) 40 (1.9) 17 (1.8) 2 (1.6)
G3-5 13 (0.4) 8 (0.4) 5 (0.5) 0 (0)
Bleeding All 40 (1.3) 24 (1.1) 15 (1.6) 1 (0.8)
G3-5 19 (0.6) 12 (0.6) 7 (0.8) 0 (0)
Gastrointestinal perforation All 8 (0.3) 5 (0.2) 3 (0.3) 0 (0)
G3-5 4 (0.1) 3 (0.1) 1 (0.1) 0 (0)
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Hypertension was reported in 71 patients (3.3%), 34 pa-
tients (3.6%), and 10 patients (7.8%) in <65 years, 65 to
75 years, and ≥75 years age group, respectively. Thrombo-
embolic event was reported in 65 (3.1%), 36 (3.9%),
and 4 (3.1%) patients aged <65 years, 65 to 75 years,
and ≥75 years, respectively. The incidence of both pro-
teinuria and bleeding did not exceed 2.0% in any age
group. Gastrointestinal perforation was recorded in 8 pa-
tients (5 aged <65 years, 3 aged 65 to 75 years). Severe
(i.e. grade ≥ 3) adverse events were rarely observed except
for hypertension and thromboembolic events, which were,
however, reported in less than 4.0% of patients across all
age groups.
Discussion
The present retrospective observational study using the
population-based CORECT registry that included more
than 1,000 mCRC patients aged ≥65 years ranks among
the largest studies published so far analysing the out-
come of treatment with bevacizumab combined with
chemotherapy in the elderly patients. Although pa-
tients ≥65 years of age represent the majority of patients
with mCRC, elderly patients are commonly underrepre-
sented in prospective randomized clinical trials, and, in
addition, there are still limited data from observational
studies about the efficacy and safety of bevacizumab-
containing therapy in this patient population.
With regard to the survival outcomes, the present
analysis shows that elderly mCRC patients receiving
bevacizumab-containing therapy, both 65 to 75 years
and ≥75 years age groups, have PFS and OS similar to
those of mCRC patients aged <65 years. These results
were confirmed in both the univariate analysis and in
the multivariable Cox model adjusted for possible con-
founding factors. The observation that patient age doesnot significantly influence PFS and OS of mCRC patients
is consistent with previously published reports [11-14].
Thus, patient age should not be considered a limiting
factor with respect to bevacizumab-containing therapy
in mCRC patients. The most significant factors with
respect to both PFS and OS were the number of meta-
static sites and the presence of metastases at diagnosis
of CRC.
In this study, the median PFS estimates for all age-
defined cohorts were higher than the PFS estimates
in the BRiTE observational study [15]. Similarly, age-
specific median OS estimates in the present analysis
were higher compared to the BRiTE study. These differ-
ences can be partly explained by an almost 20% higher
proportion of patients with synchronous metastases in
the BRiTE study. In addition, different distribution of
ECOG PS categories could also contribute to the differ-
ences in OS. While almost all (97.5%) mCRC patients
with recorded performance status information in our
cohort had a performance status of 0 or 1, the respective
percentage in the BRiTE cohort was lower (92.4%).
Moreover, the relatively favourable OS results may also
be partly attributed to the effective centralisation of
mCRC patients into comprehensive cancer centres (CCCs)
which has been implemented in the Czech Republic as of
2006 [11]. The administration of the most expensive can-
cer drugs including bevacizumab is currently concentrated
to only 13 CCCs. In comparison, the median number of
patients enrolled per centre was only 8 for the 248 sites in
the BRiTE study [8].
Other findings regarding the administration and
outcomes of anti-tumour therapy in elderly mCRC
patients were consistent with the BRiTE study. As for
chemotherapy backbone regimens, the elderly patients
received, in general, less aggressive therapy, and both
oxaliplatin and irinotecan were administered less often
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patients. In addition, the overall duration of treatment
was shorter in the elderly mCRC population compared to
younger patients [15]. The tendency to administer less
aggressive and shorter therapy can be justified by the fact
that the elderly mCRC patients were reported to experi-
ence significantly greater hematologic toxicity [17].
Regarding patients ≥75 years of age who were treated
with bevacizumab and capecitabine only, the results can
be compared with data of the AGITG MAX trial [14]
and the AVEX trial [18]. In this analysis, we observed
higher median PFS estimate and similar median OS esti-
mate compared with the corresponding estimates pub-
lished in the two trials (Table 2). However, the difference
in PSF should be assessed with caution as only 18 pa-
tients were included in the present analysis resulting in
high variability of the estimate.
Present results cannot be compared to the Surveil-
lance, Epidemiology, and End Results-Medicare linked
database analysis of Meyerhardt et al. [19] that evaluated
the effectiveness of first-line bevacizumab-containing
therapy in stage IV CRC patients aged >65 years. Firstly, a
different time period was evaluated in the U.S. study
(mCRC patients diagnosed in 2007 or earlier). Secondly,
only patients diagnosed with stage IV CRC (synchronous
metastases) were analysed and, thirdly, only patients
treated with either oxaliplatin- or irinotecan-based chemo-
therapy were considered by Meyerhardt et al.
Among the major bevacizumab-related toxicities, new
or worsening hypertension, thromboembolic events, and
proteinuria have been reported in ≥10% of patients re-
ceiving bevacizumab [13,15,20,21]. Moreover, the inci-
dence of hypertension was also found to be age-related
[22]. Bleeding, gastrointestinal perforations, and wound
healing complications were observed less often [23]. In
the present study, the above mentioned adverse events
were recorded less frequently than in previously re-
ported (Table 4). Underreporting cannot be obviously
excluded in the registry. On the other hand, when con-
sidering severe adverse events only (grade ≥ 3); the re-
sults of the present study are more consistent with those
of other reports. This implies that serious adverse events
or events leading to the treatment interruption or modi-
fication were more likely to be reported to the database.
Despite the lower incidence of adverse events, however, no
increase in bevacizumab-related toxicity among the elderly
mCRC patients was observed, the only exception being
hypertension, which occurred in approximately twice as
many patients aged ≥75 years in comparison with patients
in <65 years and 65 to 75 years age groups.
The present analysis has several limitations that can be
partly attributable to its observational nature. First and
foremost, the selection bias cannot be excluded as only
medically fit patients with very good performance statusmight have been treated with bevacizumab-containing
therapy among the elderly mCRC patients in contrast to
younger patients where indication criteria tend to be less
strict. This is suggested by the low proportion of elderly
patients in the whole cohort of bevacizumab-treated
patients and in turn might have led to more favourable
OS estimate in elderly patients. In fact, while patients
aged ≥ 65 years represent the majority of mCRC popula-
tion (64% of newly diagnosed mCRC patients in 2006–
2010 according to the Czech National Cancer Registry [2]),
in the present analysis only about a third of the patients
were aged ≥ 65 years. Secondly, the PFS estimates could
have been biased by the fact that neither independent
monitoring nor centralized review of radiological response
was performed in our study. Last but not least, in
comparison with other clinical and observational studies,
the adverse events seem to be underreported in the study
database. Moreover, only adverse events thought to be
linked to bevacizumab were consistently reported in the
registry. Although many countries have now implemented
some degree of centralisation of treatment and decision-
making in the area of targeted cancer therapies, the results
presented here may not be fully generalisable to more
decentralised health systems. Nevertheless, the 5-year rela-
tive survival of patients diagnosed with stage IV colorectal
cancer was 11.5%, a figure similar to European and US
data [24-26].
Conclusions
The present large retrospective study confirms that a se-
lected group of elderly mCRC patients fit for chemother-
apy combined with targeted therapy may derive similar
benefit in terms of improvement in OS and PFS from
bevacizumab therapy compared to younger patients. Thus,
chronological age should not be considered an exclusion
criterion for bevacizumab-containing therapy in mCRC.
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